Stryker Corporation vs Texas Instruments Incorporated — how do they compare? Stryker Corporation trades at $278.83 (market cap $106.24B), while Texas Instruments Incorporated trades at $282.57 (market cap $263.20B). The key difference: Texas Instruments Incorporated is far larger — about 2.5× Stryker Corporation's market cap, and Texas Instruments Incorporated pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and Texas Instruments Incorporated for 76 Days on average.
| SYK | TXN | |
|---|---|---|
Market Cap | $106.24B | $263.20B |
Volume | 2,982,001 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $388.35 | $332.35 |
52-Week Low | $269.75 | $153.33 |
Typical Hold Time | 20 Days | 76 Days |
Enterprise Value | $117.70B | $270.25B |
Dividend Yield | 1.27% | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Texas Instruments (TXN) trades at $288.94, down 2.82% on the day, amid a broader semiconductor sell-off. The stock maintains a bullish technical outlook with strong moving average signals and key support at $286. Fundamentally, revenue and earnings are recovering, with Q2 2026 EPS beating expectations at $2.14 versus $1.91, driven by data center sales growth and margin expansion. The company's net income margin stands at 31.11%, with robust cash flow from operations of $7.15 billion in 2025.
The outlook for TXN is positive, supported by accelerating data center demand, AI infrastructure investments, and a consensus price target of $325 implying 12% upside. Risks include premium valuation with a P/E of 43.8 and rising debt-to-asset ratio of 40.61% in 2025. Analyst sentiment is bullish with 47.69% buy ratings, though competitive pressures and cyclical semiconductor demand pose headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →